Dyne Therapeutics: Q3 Earnings Insights

Dyne Therapeutics (NASDAQ:DYN) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:28 AM. Here's what investors need to know about the announcement.

byBenzinga Insights

November 3, 2022

1 minute read

Dyne Therapeutics (NASDAQ:DYN) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:28 AM.

Here’s what investors need to know about the announcement.

Earnings

Dyne Therapeutics beat estimated earnings by 13.04%, reporting an EPS of $-0.8 versus an estimate of $-0.92.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.24 which was followed by a 1.15% increase in the share price the next day.

To track all earnings releases for Dyne Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Earnings

American Outdoor Brands’s Return On Capital Employed Insights

By Benzinga Insights

June 29, 10:45 AM

Benzinga Pro data, American Outdoor Brands (NASDAQ:AOUT) reported Q4 sales of $42.20 million. Earnings fell to a loss…

AOUT

State Street Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

By Avi Kapoor

April 12, 12:55 AM

State Street Corporation (NYSE: STT) is set to release earnings results for its first quarter before the opening bell on April 12, 2024.

STT

Organic Growth And Innovation Drive YoY Increase In Cannabis Producer Organigram’s Q4 Revenue And Adjusted EBITDA

By Jelena Martinovic

December 19, 12:41 PM

Canadian cannabis producer Organigram Holdings reported an 11% year-over-year increase in net revenue for the fourth quarter, reaching C$A161.6 million ($121 million). The company credited the growth to its focus on innovative products that meet consumer demand for convenience, such as pre-rolls and edibles. The increase in revenue contributed to a 71% rise in adjusted EBITDA to nearly CA$6m for the quarter, compared with the same period in 2022. Organigram's adjusted gross margin was CA$40.2m, up 20% on 2022. The company also reported a net loss of CA$248.6m, compared with CA$14.3m in 2022, due to impairments on property, plant and equipment, intangibles and goodwill. Organigram said it expects improved margins in future as efficiency gains from facility upgrades and expansion into higher-margin categories such as craft flower and vapes bear fruit.

OGI